The Nonnucleoside Reverse Transcriptase Inhibitors Efavirenz and Nevirapine in the Treatment of HIV

REFERENCES

• Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents: Department of Health and Human Services, Panel on Clinical Practices for Treat-ment of HIV Infections; 2003. Available at: http://www.hivatis.org.
   Google Scholar
• Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865–1873.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al, for the 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive pa-tients: a 3-year randomized trial. JAMA. 2004;292:191–201.
   PubMed Web of Science ®Google Scholar
• Gazzard BG, deJesus E, Cahn P, et al. Abacavir (ABC) once daily (OAD) plus lamivudine (3TC) OAD in combina-tion with efavirenz (EFV) OAD is well tolerated and effective in the treatment of antiretroviral (ART) naïve adults with HIV-1 infection (ZODIAC Study: CNA30021). Paper pre-sented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14–17, 2003; Chi-cago, IL.
   Google Scholar
• DeJesus E, Herrera G, Teofilo E, et al. Efficacy and safety of abacavir (ABC) versus zidovudine (ZDV) in antiretroviral therapy-naive adults with HIV-1 infection (Study CNA30024). Paper presented at: 43rd Interscience Confer-ence on Antimicrobial Agents and Chemotherapy; Sep-tember 14–17, 2003; Chicago, IL.
   Google Scholar
• van Leeuwen R, Katlama C, Murphy RL, et al. A random-ized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003;17:987–999.
   PubMed Web of Science ®Google Scholar
• van Leth F, Phanuphak P, Ruxrungtham K, et al. Compari-son of first-line antiretroviral therapy with regimens includ-ing nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004 ;363:1253–1263.
   PubMed Web of Science ®Google Scholar
• Lange JM. Efficacy and durability of nevirapine in antiretroviral drug naive patients. J Acquir Immune Defic Syndr. 2003;34\(suppl 1):540–52.
   Google Scholar
• Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279:930–937.
   PubMed Web of Science ®Google Scholar
• Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2293–2303.
   PubMed Web of Science ®Google Scholar
• Arribas J, Staszewski S, Nelson M, et al. 3-year durability of response with an Efavirenz (EFV)-containing regimen: 144 week follow-up of Study 006. In: Program and ab-stracts of the 11th European Congress of Clinical Microbi-ology and Infectious Diseases; April 1–4, 2001; Istanbul, Turkey. Absract 043.
   Google Scholar
• Gallant JE, Rodriguez A, Weinberg W, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: E5530009 unplanned interim analysis. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Che-motherapy; September 14–17, 2003; Chicago, IL. Abstract 1722a.
   Google Scholar
• Cohen C, Elion R, Green S, et al. Sustiva (efavirenz) is highly effective and well tolerated in combination with the nucleosides stavudine and lamivudine (Study DMP 266–043). Paper presented at: 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Che-motherapy; September 17–20, 2000; Toronto, Ontario, Canada.
   Google Scholar
• Montaner J, Saag MS, Barylski C, Siemon-Hryczyk P. FO-CUS Study: Saquinavir QD regimen versus efavirenz QD regimen 48 week analysis in HIV infected patients. In: Program and abstracts of the 42nd Interscience Confer-ence on Antimicrobial Agents and Chemotherapy; Sep-tember 27–30, 2002; San Diego, CA. Abstract 1–669.
   Google Scholar
• Bartlett J, Johnson J, Herrera G, Sosa N, Rodriguez A, Shaefer MS. Abacavir/lamivudine (ABC/3TC) in combina-tion with efavirenz (NNRTI), amprenavir/ritonavir (P1) or stavudine (NRTI): E5540001 (CLASS) preliminary 48 week results. In: Program and abstracts of the XIV International AIDS Conference; July 7–12, 2002; Barcelona, Spain. Ab-stract TuOrB1189.
   Google Scholar
• Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther. 2002;7: 81–90.
   PubMed Web of Science ®Google Scholar
• Podzamczer D. Final 12-month results from the Combine study: a randomized, open multicenter trial comparing Combivir (AZT/3TC) plus nelfinavir or nevirapine in HIV+ naive patients. In: Program and abstracts of the 1st IAS Conference on HIV Pathogenesis & Treatment; July 7–11, 2001; Buenos Aires, Argentina. Abstract 7.
   Google Scholar
• Nunez M, Soriano V, Martin-Carbonero L, et al. SENC (Spanish Efavirenz vs. Nevirapine Comparison) trial: a ran-domized, open-label study in HIV-infected naive individu-als. HIV Clin Trials. 2002;3(3)186–194.
   Google Scholar
• van Leth F, Andrews S, Grinsztjen B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS. 2005;19:463–471.
   PubMed Web of Science ®Google Scholar
• Wood E, Hogg RS, Heath KV, et al. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies. AIDS. 2003;17:2629–2634.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Pulido F, Miro JM, et al. High effectiveness of efavirenz-based HAART in HIV-1 infected patients with less than 100 CD4 cells/mL and opportunistic diseases. The EfaVIP-1 study. Paper presented at: AIDS 2002 XIV International AIDS Conference; July 7–12, 2002; Barcelona, Spain.
   Google Scholar
• Raffi F, Reliquet V, Podzamczer D, Pollard RB. Efficacy of nevirapine-based HAART in H1V-1-infected, treatment-na-ive persons with high and low baseline viral loads. HIV Clin Trials. 2001;2(4):317–322.
   PubMedGoogle Scholar
• Katlama C, Staszewski S, Clumeck N, et al. Successful substitution of protease inhibitors with efavirenz in patients with undetectable plasma HIV-1 RNA levels: 48 week re-sults of a prospective, randomized, multicenter, open-label study (DMP 266–027). In: Program and abstracts of the 5th International Conference on Drug Therapy in HIV Infection; October 22–26, 2000; Glasgow, United Kingdom. Abstract LbPeB7044.
   Google Scholar
• Becker S, Rachlis A, Gill J, et al. Successful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral loads-a prospective, randomized, multicenter, open-label study (DMP 049). In: Program and abstracts of the 8th Conference on Retroviruses and Op-portunistic Infections; February 4–8, 2001; Chicago, IL. Abstract 20.
   Google Scholar
• Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing pro-tease inhibitors by nevirapine in HIV-infected subjects un-der long-term successful triple combination therapy. AIDS. 2000;14:807–812.
   PubMed Web of Science ®Google Scholar
• Dieleman JP, Sturkenboom MC, Wit RN, et al. Low risk of treatment failure after substitution of nevirapine for pro-tease inhibitors among human immunodeficiency virus-infected patients with virus suppression. J Infect Dis. 2002;185:1261–1268.
   PubMed Web of Science ®Google Scholar
• Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349:1036–1046.
   PubMed Web of Science ®Google Scholar
• Negredo E, Cruz L, Paredes R, et al. Virological, immuno-logical, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis. 2002;34:504–510.
   PubMed Web of Science ®Google Scholar
• Saag MS, Powderly WG, Schambelan M, et al. Switching antiretroviral drugs for treatment of metabolic complica-tions in HIV-1 infection: summary of selected trials. Topics HIV Med. 2002;10:47–51.
   Google Scholar
• Carr A, Samaras K, Burton S, et al. A syndrome of periph-eral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–58.
   PubMed Web of Science ®Google Scholar
• Fontas E, Van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination therapy: Are differ-ent antiretroviral drugs associated with different lipid pro-files? J Infect Dis. 2004;189:1056–1074.
   Google Scholar
• Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet. 1998;351:1328.
   PubMed Web of Science ®Google Scholar
• Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV pro-tease inhibitors. Lancet. 1998;351:1958.
   PubMed Web of Science ®Google Scholar
• Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M. Vascular complications associated with use of HIV protease inhibi-tors. Lancet. 1998;351:1958–1959.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.
   PubMed Web of Science ®Google Scholar
• Moore R. Increasing incidence of cardiovascular disease in HIV-infected persons in care. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston, MA. Abstract 132.
   Google Scholar
• Klein D. Hospitalizations for coronary heart disease and myocardial infarction among men with HIV-1 infection: ad-ditional follow-up. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston, MA. Abstract 747.
   Google Scholar
• Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702–710.
   PubMed Web of Science ®Google Scholar
• Fisac C, Fumero E, Roson B et al. Metabolic changes in patients switching from a protease inhibitor-containing regimen to abacavir, efavirenz or nevirapine: 24 month results of a randomized study. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2004; San Francisco, CA. Ab-stract 78.
   Google Scholar
• van Leth F, Phanuphak P, Gazzard B, et al. Lipid changes in a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine (2NN Study). In: Program and abstracts of the 10th Conference on Retroviruses and Op-portunistic Infections; February 10–14, 2003; Boston, MA. Abstract 752.
   Google Scholar
• Efavirenz (Sustiva). Physicians' Desk Reference. Montvale, NJ: Medical Economics Co., Inc.; 2005:1069–1075.
   Google Scholar
• Nevirapine (Viramune). Physicians' Desk Reference. Montvale, NJ: Medical Economics Co., Inc.; 2005:1013–1019.
   Google Scholar
• Montaner JSG, Cahn P, Zala C, et al, for the 1100.1286 Study Team. Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J Acquir Immune Defic Syndr. 2003;33:41–46.
   PubMed Web of Science ®Google Scholar
• Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr. 2003;34\(suppl 1):521–533.
   Google Scholar
• Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS. 2004;18:767–774.
   PubMed Web of Science ®Google Scholar
• Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 2005;40:588–593.
   PubMed Web of Science ®Google Scholar
• R-Novoa S, Barreiro P, Rendon A, Gonzalez-Lahoz J, Soriano V. G516T polymorphism at the CYP2B6 isoen-zyme significantly influences efavirenz plasma levels and the risk of neurological symptoms. Poster presented at: 12th Conference on Retroviruses and Opportunistic Infec-tions; February 22–25, 2005; Boston, MA.
   Google Scholar
• Gallego L, Barreiro P, del Rio R, et al. Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clin Infect Dis. 2004;38:430–432.
   PubMed Web of Science ®Google Scholar
• Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS. 2005;19:97–99.
   PubMed Web of Science ®Google Scholar